Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


How to Perform the Perfect Bone Marrow Biopsy

October 31st 2011

Obtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.

Public Speaking Tips for Fellows

October 31st 2011

All fellows will at some point in their careers be required to speak in public. This article provides a number of tips to make that task easier.

Physicians Uniting to Battle Flawed Medicare Reimbursement Formula

October 24th 2011

As millions of Americans grapple with changes in Medicare and other health insurance coverage, thousands of oncologists could find their medical practices threatened by insolvency.

A Ponzi Scheme: Investments, Social Security, Healthcare

October 19th 2011

Here are a few incontrovertible facts: our population is growing and aging; people are living longer; and care is more complex and applied for longer periods, so it is more costly.

Dr. Langer on Cost Analysis in the Treatment Decision

October 13th 2011

Dr. Corey Langer from Abramson Cancer Center on Cost Analysis in the Treatment Decision

Oncogenic Signaling of the EGFR: Familiar Target Faces New Questions

October 3rd 2011

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

New Frontiers in the Management of Solid and Liquid Tumors Letter from Andre Goy, MD, MS

October 1st 2011

A Letter from Andre Goy, MD, MS, about the New Frontiers in the Management of Solid and Liquid Tumors in November.

Taller Women May Be at Increased Risk of Cancer

September 28th 2011

British investigators are reporting that taller women have a higher risk of cancer, and that the link between height and cancer risk exists for most types of cancer.

Joint Commission Names Top-Performing Hospitals

September 22nd 2011

The Joint Commission has released this year's list of top-performing hospitals.

Five Steps to Financial Security for Fellows

September 15th 2011

The first few years after medical school can seem financially suffocating for young physicians.

Are You Thinking About Starting a Medical Practice?

September 14th 2011

With the right game plan, you can open your own lucrative practice in an area previously thought to be unprofitable.

Dr. Tripathy Discusses Biomarker Use in Clinical Trials

September 12th 2011

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Introducing Humanities Into the Oncology Curriculum

September 9th 2011

It seems that every year, the list of Accreditation Council for Graduate Medical Education (ACGME) requirements grows longer and more bewildering.

Publish or Perish: Insider Tips for Publishing in Peer-Reviewed Journals for Fellows

September 8th 2011

Researchers and clinicians are not necessarily expected to be world-class writers, but a well-written article that effectively communicates the topic at hand and adheres to the journal's standards is more likely to be published.

Healthcare Reform and the Future of Oncology

September 7th 2011

The healthcare system in the United States has become increasingly unsustainable.

Dr. Ellis on Ki67 as Treatment Monitoring Biomarkers

August 31st 2011

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

FDA Approves Crizotinib for Late-Stage Non-Small Cell Lung Cancer

August 26th 2011

On Friday, August 26, 2011, the FDA approved crizotinib (Xalkori) to treat ALK-positive patients with late-stage non–small cell lung cancer (NSCLC).

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

Dr. Ellis Discusses the Cell-Proliferation Marker Ki67

August 24th 2011

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

Dr. West Talks About the Escalating Cost of Cancer Care

August 4th 2011

Dr. Jack West from the Swedish Cancer Institute Talks About the Escalating Cost of Cancer Care

NEXT PAGE
PREVIOUS PAGE